FDA Approves Amgen's Groundbreaking LUMAKRAS Combination Therapy for Colorectal Cancer Treatment

Amgen (NASDAQ:AMGN) has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for treating adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). The approval is based on the Phase 3 CodeBreaK 300 study results.